Venture Kick

REMUUN is a biotechnology company focused on revolutionizing the development of therapeutic antibodies. It has created the MEGA platform, which mimics natural antibody gene modification and employs AID-based gene editing. This technology enables clients to accelerate, reduce costs, and enhance precision in the creation of monoclonal antibody therapies.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments

Shape Biopharmaceuticals is a biotechnology company that specializes in the development of immunotherapeutic drugs aimed at treating chronic diseases with limited treatment options. The company focuses on advanced protein design and formulation technologies to create a new generation of immunotherapies. By addressing unmet medical needs, Shape Biopharmaceuticals seeks to improve patient outcomes for individuals with genetically driven conditions who lack effective therapeutic alternatives. Through its innovative healthcare solutions, the company aims to provide hope and enhance treatment possibilities for patients facing significant health challenges.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Amporin Pharmaceuticals seeks to create a new class of small-molecule medications that block and eradicate harmful soluble oligomers and holes found within cell membranes.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

Procavea Biotech specializes in developing a drug delivery system based on non-viral protein cages for targeted therapeutic applications.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

ASTRA Therapeutics is a medication development company focused on creating innovative therapies for parasitic diseases. Utilizing advanced science and technology, the company develops precision-engineered drugs to combat a wide range of parasitic disorders, including malaria, cryptosporidiosis, and toxoplasmosis. Its mission is to address the global health burden posed by these conditions by bringing effective treatment candidates to market.

metaLead Therapeutics is developing a short peptide medication designed to revolutionize the treatment of metal-related diseases. Its approach involves selectively capturing toxic metals for targeted removal, while preserving essential ones, thereby improving efficacy and minimizing side effects.

Tandem Therapeutics is a biopharmaceutical company dedicated to pioneering treatments for fibrotic diseases. It focuses on the extracellular matrix, a complex network of proteins that surrounds cells, and develops peptide therapeutics, known as Matrix Targeting Peptides (MTPs), to target and treat the extracellular matrix barrier. This innovative approach aims to provide more precise and effective treatments for patients suffering from fibrotic conditions, including cancers and organ fibrosis.

Aukera Therapeutics is a biotechnology company focused on developing innovative therapeutics targeting the mTOR protein pathway. Its primary focus lies in treating diseases such as cancer and neurodegenerative disorders.

Biosimo is a startup focused on developing processes to produce bio-based platform chemicals. Its innovative approach involves using ethanol derived from biomass and waste to create sustainable alternatives to fossil fuel-based chemicals, catering primarily to the chemical, pharmaceutical, and material industries.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Biosimo is a startup focused on developing processes to produce bio-based platform chemicals. Its innovative approach involves using ethanol derived from biomass and waste to create sustainable alternatives to fossil fuel-based chemicals, catering primarily to the chemical, pharmaceutical, and material industries.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

ArcoScreen is a Swiss medtech company developing a microfluidic discovery platform for drug screening that targets membrane receptors, notably G-protein coupled receptors. The platform blends a lab-on-chip system with biological assays to quantify GPCR activation in primary mammalian cells, including guanosine 5'-O-(3-thiotriphosphate)-based functional readouts, and supports both ready-to-use and custom stable cell lines. This approach enables pharmaceutical researchers to investigate receptor signaling, identify drug modes of action, and perform in-vitro screenings directly on patient-derived cells. By enabling faster, more predictive screenings, ArcoScreen aims to reduce clinical attrition and accelerate the development of therapeutic candidates with improved translational relevance.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

microPow specializes in developing clean-label encapsulation systems for active ingredients, focusing on food, cosmetics, and pharmaceutical applications. Its core technology provides an all-natural delivery system for aromas and flavors, enhancing storability and release, and enabling timed release capabilities.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

Microcaps develops microencapsulation technology that protects and controls the release of active ingredients in pharmaceuticals, probiotics, and cosmetic formulations. Leveraging microfluidics and step emulsification, the company produces monodisperse microcapsules and microparticles at scale, enabling precise size control, dosing, and greater stability. Its platform supports liquid oil core microcapsules with natural alginate shells, improving throughput without quality loss. Based in Zurich, Switzerland, Microcaps targets applications across drug delivery, probiotic encapsulation, and fragrance or cosmetic encapsulation, offering automated encapsulation production capable of high-throughput manufacturing for complex formulations.

Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Prolongate is a protein drugs and biotech company.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

microPow specializes in developing clean-label encapsulation systems for active ingredients, focusing on food, cosmetics, and pharmaceutical applications. Its core technology provides an all-natural delivery system for aromas and flavors, enhancing storability and release, and enabling timed release capabilities.

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Microcaps develops microencapsulation technology that protects and controls the release of active ingredients in pharmaceuticals, probiotics, and cosmetic formulations. Leveraging microfluidics and step emulsification, the company produces monodisperse microcapsules and microparticles at scale, enabling precise size control, dosing, and greater stability. Its platform supports liquid oil core microcapsules with natural alginate shells, improving throughput without quality loss. Based in Zurich, Switzerland, Microcaps targets applications across drug delivery, probiotic encapsulation, and fragrance or cosmetic encapsulation, offering automated encapsulation production capable of high-throughput manufacturing for complex formulations.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

microPow specializes in developing clean-label encapsulation systems for active ingredients, focusing on food, cosmetics, and pharmaceutical applications. Its core technology provides an all-natural delivery system for aromas and flavors, enhancing storability and release, and enabling timed release capabilities.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Microcaps develops microencapsulation technology that protects and controls the release of active ingredients in pharmaceuticals, probiotics, and cosmetic formulations. Leveraging microfluidics and step emulsification, the company produces monodisperse microcapsules and microparticles at scale, enabling precise size control, dosing, and greater stability. Its platform supports liquid oil core microcapsules with natural alginate shells, improving throughput without quality loss. Based in Zurich, Switzerland, Microcaps targets applications across drug delivery, probiotic encapsulation, and fragrance or cosmetic encapsulation, offering automated encapsulation production capable of high-throughput manufacturing for complex formulations.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

Lipidon is a bioanalytical service company that specializes in lipid research and lipidomics analytical services. The company focuses on identifying and developing novel biomarkers tailored for the life sciences, cosmetic, and food industries. By providing actionable biomarker discovery, Lipidon aids in precision medicine and various sectors, including pharmaceuticals, biotechnology, cosmetics, and food. The company’s services enable clients to distinguish between products of animal and herbal origin, facilitating informed decision-making in their respective fields.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

INOFEA AG is a Swiss biotech company established in 2011, headquartered in Basel. The company specializes in developing patented platform technology that enhances the stability and usability of enzymes for various applications in the pharmaceutical and consumer healthcare sectors. INOFEA's innovative enzyme shielding technology immobilizes and protects fragile enzymes, allowing them to be effectively utilized in in vivo conditions, including digestive health products and personal care items. Additionally, the technology improves industrial biocatalytic processes, addressing the challenges commonly associated with enzyme stability and robustness.

APERI pharmaceuticals is a biotech in the launch phase developed around an oral biologics delivery platform. With already 2 patents filed and about 7 years of specific research and development we initially target the lucrative Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). AP09 is a novel permeation enhancer and forms the cornerstone of our technology. It allows macromolecules to diffuse through the tight space between cells, known as tight junctions, where they won’t do it under normal conditions. AP09 adopts a unique, mechanism-based, target selective, trans-mucosal permeation enhancers that offer maximum safety index, highly reversible effect and can transport antibodies without causing any toxicity.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Founded in 2017, Scailyte specializes in developing artificial intelligence-based software solutions. It offers ScaiVision, a tool for analyzing single-cell data in biomedical research and pharmaceutical discovery, along with biomarker discovery services for businesses.

MesenFlow Technologies specializes in innovative bio-imaging technology aimed at enhancing drug and cosmetic development. The company’s platform addresses critical challenges in modern drug development, including species cross-reactivity and the ethical concerns of animal testing. By utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and its relevance to human biology. This approach not only accelerates the pharmaceutical testing process but also extends to the cosmetics and nutraceutical sectors, allowing for the assessment of product safety and efficacy at an early stage. MesenFlow's technology is particularly beneficial for organizations requiring animal-free testing solutions, ensuring compliance with regulatory demands while prioritizing human biological impact.

Modum is a Zurich-based startup aims to provide an Internet of Things (IoT)-based supply chain logistics solution to help European companies comply with European Commission regulations for pharmaceutical transport. Modum sensors will record environmental data during shipments to ensure they comply with both supplier-customer contracts and government regulations.

Founded in 2016 and based in Zurich, Switzerland, Synple Chem specializes in the manufacture of automated reagent cartridge-based synthesizers. Its products, such as Synple 1 and Synple 2, accelerate drug research by enabling rapid synthesis of molecules, improving efficiency, and reducing reaction times.

Modum is a Zurich-based startup aims to provide an Internet of Things (IoT)-based supply chain logistics solution to help European companies comply with European Commission regulations for pharmaceutical transport. Modum sensors will record environmental data during shipments to ensure they comply with both supplier-customer contracts and government regulations.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

APERI pharmaceuticals is a biotech in the launch phase developed around an oral biologics delivery platform. With already 2 patents filed and about 7 years of specific research and development we initially target the lucrative Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). AP09 is a novel permeation enhancer and forms the cornerstone of our technology. It allows macromolecules to diffuse through the tight space between cells, known as tight junctions, where they won’t do it under normal conditions. AP09 adopts a unique, mechanism-based, target selective, trans-mucosal permeation enhancers that offer maximum safety index, highly reversible effect and can transport antibodies without causing any toxicity.

Selmod, based in Basel's life science hub, develops innovative antibiotics targeting multi-drug resistant infections. Its first-in-class drug candidates focus on high-revenue hospital patients where first-line treatments have failed due to resistance. With a disruptive approach featuring new dual modes of action, all candidates have shown success in animal infection studies. The company aims to capture a significant share of the estimated $9 billion total available market for its three lead assets.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

DermAbiotech develops innovative targeted therapies for acute T cell-mediated inflammatory diseases.

Enzian Pharmaceutics specializes in manufacturing pharmaceutical products, focusing on oral solid dosage forms designed to deliver drugs into the bloodstream at a constant rate. This approach aims to achieve steady concentrations within the optimal range, enabling faster therapeutic responses and reduced side effects.

Founded in 2015 as a spin-off of ETH Zurich, Inositec is a biotechnology company that develops novel therapies for soft tissue calcification disorders. It leverages its proprietary Inositune platform to engineer small molecules with tunable properties, focusing on vascular and renal calcification disorders, including orphan indications.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

Enzian Pharmaceutics specializes in manufacturing pharmaceutical products, focusing on oral solid dosage forms designed to deliver drugs into the bloodstream at a constant rate. This approach aims to achieve steady concentrations within the optimal range, enabling faster therapeutic responses and reduced side effects.

Modum is a Zurich-based startup aims to provide an Internet of Things (IoT)-based supply chain logistics solution to help European companies comply with European Commission regulations for pharmaceutical transport. Modum sensors will record environmental data during shipments to ensure they comply with both supplier-customer contracts and government regulations.

NeuroCycle Therapeutics, founded in 2018 and based in Cambridge, Massachusetts, is a biopharmaceutical company specializing in the development of small molecule drugs that target the nervous system. The company's primary focus is on sub-type selective GABA-A modulation, aiming to deliver next-generation treatments for chronic itch, pain, and certain refractory forms of pediatric epilepsy. Their lead candidate, NCT10004, has demonstrated significant efficacy across various models without causing sedation, immune suppression, dependency/addiction issues, or losing effectiveness over time.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

AlveoliX is a Swiss biotechnology company based in Bern that develops organ-on-chip based in vitro lung models to support preclinical decision-making in drug development. Its lung-on-chip platforms reproduce key biophysical features of the lung to better predict human drug responses, with the goal of improving safety, reducing costs, and decreasing reliance on animal testing.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

AlveoliX is a Swiss biotechnology company based in Bern that develops organ-on-chip based in vitro lung models to support preclinical decision-making in drug development. Its lung-on-chip platforms reproduce key biophysical features of the lung to better predict human drug responses, with the goal of improving safety, reducing costs, and decreasing reliance on animal testing.

PB&B SA is an early-stage Life Sciences company established in 2013 by a collaboration of bioengineers, plastic surgeons, and scientists. The company focuses on creating natural and minimally invasive solutions for facial aging and body remodeling. PB&B has developed a proprietary injection that enhances adipose (fat) volume in situ through advanced microencapsulation and drug delivery technologies. This innovative approach aims to address underserved needs in the rapidly growing body shaping market, offering a safer and more efficient alternative to traditional fat transfer procedures. The company's products are specifically designed for plastic surgeons and aesthetic injectors involved in body shaping treatments for various applications, including facial, hand, décolleté, and buttock enhancements.

PB&B SA is an early-stage Life Sciences company established in 2013 by a collaboration of bioengineers, plastic surgeons, and scientists. The company focuses on creating natural and minimally invasive solutions for facial aging and body remodeling. PB&B has developed a proprietary injection that enhances adipose (fat) volume in situ through advanced microencapsulation and drug delivery technologies. This innovative approach aims to address underserved needs in the rapidly growing body shaping market, offering a safer and more efficient alternative to traditional fat transfer procedures. The company's products are specifically designed for plastic surgeons and aesthetic injectors involved in body shaping treatments for various applications, including facial, hand, décolleté, and buttock enhancements.

Market Access Companion offers big data-driven decision support for the health and life sciences industries.

Nanolive SA is a Swiss company that specializes in the design and development of advanced imaging devices for live cells. Established in 2013 and headquartered in Ecublens, Switzerland, the company offers the 3D Cell Explorer, a cutting-edge technology that allows researchers to visualize the interior of living cells in three dimensions without the need for labeling or invasive techniques. This innovative device enables detailed observation of various cellular processes such as cell division, organelle structure, cell morphology, differentiation, and interactions between cells. By capturing unbiased live cell data, Nanolive's technology supports the research and development of new drugs and therapies, facilitating quality analysis and providing valuable biological insights for scientists and researchers in the field of life sciences.

PB&B SA is an early-stage Life Sciences company established in 2013 by a collaboration of bioengineers, plastic surgeons, and scientists. The company focuses on creating natural and minimally invasive solutions for facial aging and body remodeling. PB&B has developed a proprietary injection that enhances adipose (fat) volume in situ through advanced microencapsulation and drug delivery technologies. This innovative approach aims to address underserved needs in the rapidly growing body shaping market, offering a safer and more efficient alternative to traditional fat transfer procedures. The company's products are specifically designed for plastic surgeons and aesthetic injectors involved in body shaping treatments for various applications, including facial, hand, décolleté, and buttock enhancements.

TransCure BioServices SAS is a biotechnology company based in Archamps, France, founded in 2012. The company specializes in vivo pharmacology preclinical services and offers unique research and development platforms, including its Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. These innovative models are designed to enhance the drug profiling and development process for pharmaceutical companies, biotech firms, and academic researchers focusing on immuno-related diseases and anti-HIV/AIDS therapies. By providing access to its specialized platforms as fee-for-service offerings, TransCure BioServices enables clients to efficiently generate and characterize humanized mouse models that deliver predictive insights into human drug responses. This capability helps accelerate the development and commercialization of new therapies, ultimately allowing clients to bring effective treatments to market more quickly and cost-effectively.